Ghrelin: Growth Hormone Secretagogue Receptor Signaling, Hunger Pathway Research & Reward Circuit Biology

The Hunger Hormone’s Deeper Story

Ghrelin occupies a unique position in peptide biology. Discovered in 1999 by Masayasu Kojima and colleagues at Kurume University, it was identified through reverse pharmacology — researchers found the receptor first (growth hormone secretagogue receptor type 1a, GHS-R1a), then went searching for its endogenous ligand. What they found was a 28-amino-acid peptide produced primarily by oxyntic cells in the gastric fundus, bearing a distinctive octanoyl modification on its third serine residue.

That fatty acid modification is not decorative. Without the octanoyl group attached by the enzyme ghrelin O-acyltransferase (GOAT), the peptide cannot activate GHS-R1a. This requirement for acylation makes ghrelin the only known peptide hormone requiring a post-translational lipid modification for receptor activation — a feature that has fascinated biochemists and created a natural drug design target in the GOAT enzyme.

GHS-R1a: A Receptor with Constitutive Activity

GHS-R1a is remarkable in its own right. Unlike most G-protein-coupled receptors, which remain silent until a ligand arrives, GHS-R1a displays approximately 50% constitutive activity. In the absence of any ghrelin, the receptor signals at half-maximal capacity. Ghrelin binding pushes activity higher; inverse agonists push it lower.

This baseline signaling has significant research implications. It means that the ghrelin system is never truly “off.” Appetite, growth hormone pulsatility, and reward circuitry are all tonically influenced by GHS-R1a activity even under fasting conditions when circulating ghrelin concentrations are highest. Researchers designing experiments with GHS-R1a must account for this constitutive signaling, as receptor deletion produces effects that exceed what ghrelin removal alone would predict.

Growth Hormone Release

Ghrelin’s name derives from its growth hormone-releasing activity — “ghre” from the Proto-Indo-European root meaning “to grow.” Upon reaching the anterior pituitary via the bloodstream, acyl-ghrelin binds GHS-R1a on somatotroph cells and triggers growth hormone (GH) secretion through a phospholipase C-dependent calcium signaling cascade.

This GH-releasing effect is synergistic with growth hormone-releasing hormone (GHRH). In isolated pituitary cell assays, co-administration of ghrelin and GHRH produces GH release exceeding the sum of either agent alone. The synergy involves distinct but converging intracellular pathways: GHRH signals through cAMP/PKA while ghrelin signals through IP3/DAG/PKC. This convergence amplifies calcium influx beyond what either pathway generates independently.

Appetite Circuits and the Gut-Brain Axis

Ghrelin concentrations in blood follow a striking preprandial pattern. Levels rise sharply before anticipated meals and plummet within minutes of eating. This prandial rhythm — the only gut hormone that rises before meals rather than after — earned ghrelin its reputation as the hunger hormone.

But the appetite story extends beyond simple hunger signaling. Ghrelin acts on NPY/AgRP neurons in the hypothalamic arcuate nucleus, activating the same orexigenic circuits that NPY stimulates. Vagal afferents from the stomach also carry ghrelin signals to the nucleus tractus solitarius in the brainstem, providing a parallel hunger input that bypasses the hypothalamus entirely.

In rodent studies, chronic ghrelin infusion increases not just meal size but also meal frequency and shifts macronutrient preference toward carbohydrates and fats. Whether these effects translate proportionally to complex organisms remains under investigation, but the directionality is consistent across species studied to date.

Reward, Motivation, and Dopamine

Some of the most provocative ghrelin research has focused on the mesolimbic dopamine system — the brain’s reward circuitry. GHS-R1a is expressed on dopaminergic neurons in the ventral tegmental area (VTA), and ghrelin injection into the VTA increases dopamine release in the nucleus accumbens. The behavioral correlate: enhanced motivation for food reward in operant conditioning paradigms.

This finding repositioned ghrelin from a simple hunger signal to a modulator of wanting — the motivational drive to seek and work for rewards. The distinction matters. Hunger increases the hedonic value of food, but ghrelin specifically amplifies the effort animals will expend to obtain it. In progressive ratio experiments, ghrelin-treated rodents press levers far more times for a food pellet compared to controls, even when both groups are equally food-deprived.

Intriguingly, GHS-R1a also forms heterodimers with dopamine D1 and D2 receptors, altering their signaling properties. These receptor-receptor interactions add a layer of complexity that may explain why ghrelin’s reward-modulating effects do not simply mirror those of direct dopamine agonists.

Des-Acyl Ghrelin: The Other Form

Approximately 80-90% of circulating ghrelin lacks the octanoyl modification and is designated des-acyl ghrelin. Initially dismissed as an inactive degradation product, des-acyl ghrelin has since been shown to produce distinct biological effects — sometimes opposing those of acyl-ghrelin. In certain experimental contexts, des-acyl ghrelin reduces food intake and inhibits gastric emptying, acting through receptors that remain incompletely characterized.

The acyl/des-acyl ratio therefore matters. Changes in GOAT expression, dietary fatty acid availability (octanoic acid is a medium-chain fatty acid found in coconut and palm kernel oil), and degradation kinetics all influence this ratio. Researchers measuring “total ghrelin” without distinguishing acylation status may miss functionally relevant shifts in the balance between these two forms.

Current Research Directions

Active ghrelin research spans multiple frontiers. In metabolic science, GOAT inhibitors are being evaluated as tools to reduce acyl-ghrelin production selectively. In neuroscience, GHS-R1a’s role in alcohol and substance reward pathways has attracted attention from addiction researchers. And in aging biology, the age-related decline in ghrelin pulsatility — paralleling GH decline — raises questions about whether diminished ghrelin signaling contributes to sarcopenia and frailty in aging research models.

Disclaimer: This content is intended for research purposes only and is not meant to constitute medical advice.